This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.70% per year. These returns cover a period from January 1, 1988 through November 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical-devices: Archive
GE HealthCare Wins FDA Nod for AI Feeding Tube Detection Software
by Zacks Equity Research
GEHC secures FDA clearance for AI-powered feeding tube detection software, expanding bedside X-ray capabilities for adult and pediatric patients.
GEHCNegative Net Change ISRGNegative Net Change WSTNegative Net Change GKOSPositive Net Change
medical medical-devices
Here's Why You Should Retain NeuroPace Stock in Your Portfolio for Now
by Zacks Equity Research
NPCE's RNS adoption, new indications and reimbursement gains offer growth potential, but weak sales execution and regulatory hurdles pose near-term risks.
NPCENegative Net Change ISRGNegative Net Change WSTNegative Net Change GKOSPositive Net Change
medical medical-devices
Philips Unveils Skylight Device Manager to Boost Ultrasound Efficiency
by Zacks Equity Research
PHG launches cloud-based Skylight Device Manager to optimize ultrasound fleet management, boost equipment utilization and streamline healthcare operations.
PHGNegative Net Change ISRGNegative Net Change WSTNegative Net Change GKOSPositive Net Change
medical medical-devices
Should You Buy Lionsgate Studios Corp. (LION) After Golden Cross?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
LIONNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
The RealReal (REAL) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
REALNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy MannKind (MNKD) After Golden Cross?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
MNKDNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Implied Volatility Surging for Urogen Pharma Stock Options
by Zacks Equity Research
Investors need to pay close attention to URGN stock based on the movements in the options market lately.
URGNPositive Net Change
medical medical-devices
MiniMed Launches MiniMed Flex Pump in Europe to Expand Diabetes Care (Revised)
by Zacks Equity Research
MMED launches compact Flex insulin pump in Europe, combining app-based control and SmartGuard technology to expand diabetes care portfolio and reach.
MMEDNegative Net Change MMSINegative Net Change OPKNegative Net Change GMEDNegative Net Change
medical medical-devices
Reasons to Add West Pharmaceutical Stock to Your Portfolio Now
by Zacks Equity Research
West Pharmaceutical's growth prospects are fueled by strong HVP demand, expanding biologics exposure and regulatory upgrades, despite near-term headwinds.
WSTNegative Net Change ISRGNegative Net Change CAHNegative Net Change GKOSPositive Net Change
medical medical-devices
Is This the Right Time to Retain Omnicell Stock in Your Portfolio?
by Zacks Equity Research
OMCL advances its growth strategy through Titan XT, OmniSphere and recurring revenues, while cost discipline boosts profitability.
OMCLNegative Net Change IDXXNegative Net Change PODDNegative Net Change BLCONegative Net Change
medical medical-devices